ArticleActa parasitologica2025
Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis remains a significant global health concern, ranking among the top ten infectious diseases and causing substantial mortality and socioeconomic burden. Effective and accessible treatments are needed. This study investigated the potential of a hydroalcoholic extract from readily available urban green algae as an anti-leishmanial agent, focusing on its impact on key weight-related indicators of Leishmania major infection in BALB/c mice. To evaluate the in vivo anti-leishmanial activity of the hydroalcoholic extract from the common green algae genus Spirogyra against Leishmania major in BALB/c mice, specifically by assessing its effects on weight loss, lesion size, liver weight, and spleen weight-key indicators of disease progression.
methodsSpirogyra algae were collected and identified in Yazd Province, Iran. A hydroalcoholic extract was prepared and administered via intraperitoneal injection into Leishmania major-infected BALB/c mice at doses of 3, 6, and 12 mg/kg/day, starting after lesion development. The control groups included untreated infected mice (negative control), healthy uninfected mice (control), and infected mice treated with Glucantime (positive control). We assessed treatment efficacy by monitoring weight loss, lesion diameter, liver weight, and spleen weight.
resultsTreatment with the highest concentration of Spirogyra extract (12 mg/kg/day) significantly mitigated weight loss in infected mice, demonstrating comparable efficacy to Glucantime. Both the 12 mg/kg/day algae extract and Glucantime significantly controlled lesion growth. Importantly, both treatments significantly reduced liver and spleen weight compared with the negative control group, indicating a reduction in organomegaly. Specifically, the negative control and 3 mg/kg extract groups exhibited the highest liver weights, whereas the negative control group showed significantly higher spleen weights than the other groups. The 12 mg/kg extract and Glucantime groups showed liver and spleen sizes comparable to the healthy control group, demonstrating effective control of organ size changes associated with leishmaniasis.
conclusionThe hydroalcoholic extract of urban Spirogyra green algae, particularly at a dose of 12 mg/kg/day, exhibited significant in vivo anti-leishmanial activity in BALB/c mice. Evaluated through weight indicators such as reduced weight loss, controlled lesion growth, and normalized liver and spleen weights, the extract showed promise in mitigating the detrimental effects of Leishmania major infection and warrants further investigation as a potential source for novel anti-leishmanial therapeutics.
Indexed as
Identifiers
39918617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.